- Coordinates
- PDB Format
- Method
- ELECTRON MICROSCOPY
- Oligo State
- hetero-3-3-3-3-mer
- Ligands
- 18 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 3 x NAG- NAG- BMA- MAN- MAN- MAN: alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
NAG-NAG-BMA-MAN-MAN-MAN.5: 9 residues within 4Å:- Chain A: E.181, P.182, V.224, L.231, N.232, G.348, V.414, S.415
- Ligands: NAG.30
3 PLIP interactions:3 interactions with chain A- Hydrophobic interactions: A:V.414
- Hydrogen bonds: A:G.348, A:V.414
NAG-NAG-BMA-MAN-MAN-MAN.13: 9 residues within 4Å:- Chain E: E.181, P.182, V.224, L.231, N.232, G.348, V.414, S.415
- Ligands: NAG.43
3 PLIP interactions:3 interactions with chain E- Hydrophobic interactions: E:V.414
- Hydrogen bonds: E:G.348, E:V.414
NAG-NAG-BMA-MAN-MAN-MAN.21: 9 residues within 4Å:- Chain I: E.181, P.182, V.224, L.231, N.232, G.348, V.414, S.415
- Ligands: NAG.56
3 PLIP interactions:3 interactions with chain I- Hydrophobic interactions: I:V.414
- Hydrogen bonds: I:G.348, I:V.414
- 3 x NAG- NAG- FUC: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-[alpha-L-fucopyranose-(1-6)]2-acetamido-2-deoxy-beta-D-glucopyranose
NAG-NAG-FUC.7: 4 residues within 4Å:- Chain B: N.100, S.102, Y.127, I.130
1 PLIP interactions:1 interactions with chain B- Hydrophobic interactions: B:Y.127
NAG-NAG-FUC.15: 4 residues within 4Å:- Chain F: N.100, S.102, Y.127, I.130
1 PLIP interactions:1 interactions with chain F- Hydrophobic interactions: F:Y.127
NAG-NAG-FUC.23: 4 residues within 4Å:- Chain J: N.100, S.102, Y.127, I.130
1 PLIP interactions:1 interactions with chain J- Hydrophobic interactions: J:Y.127
- 39 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
NAG.25: 4 residues within 4Å:- Chain A: N.204, E.245, N.246
- Ligands: NAG-NAG.3
Ligand excluded by PLIPNAG.26: 3 residues within 4Å:- Chain A: S.357, N.361
- Ligands: NAG-NAG.4
Ligand excluded by PLIPNAG.27: 2 residues within 4Å:- Chain A: N.308, T.363
Ligand excluded by PLIPNAG.28: 6 residues within 4Å:- Chain A: N.265, T.267, H.299, N.301, T.383, R.412
Ligand excluded by PLIPNAG.29: 4 residues within 4Å:- Chain A: Q.263, N.265, N.301, S.303
Ligand excluded by PLIPNAG.30: 4 residues within 4Å:- Chain A: N.232, S.261, N.416
- Ligands: NAG-NAG-BMA-MAN-MAN-MAN.5
Ligand excluded by PLIPNAG.31: 4 residues within 4Å:- Chain A: N.271, I.292, G.409, V.410
Ligand excluded by PLIPNAG.32: 4 residues within 4Å:- Chain A: Q.100, S.120, F.121, N.122
Ligand excluded by PLIPNAG.33: 4 residues within 4Å:- Chain A: R.162, N.167, T.168
- Chain I: R.278
Ligand excluded by PLIPNAG.34: 1 residues within 4Å:- Chain A: N.103
Ligand excluded by PLIPNAG.35: 1 residues within 4Å:- Chain A: N.324
Ligand excluded by PLIPNAG.36: 4 residues within 4Å:- Chain A: E.238, E.239, N.259, E.260
Ligand excluded by PLIPNAG.37: 3 residues within 4Å:- Chain B: N.107, E.110
- Chain C: T.56
Ligand excluded by PLIPNAG.38: 4 residues within 4Å:- Chain E: N.204, E.245, N.246
- Ligands: NAG-NAG.11
Ligand excluded by PLIPNAG.39: 3 residues within 4Å:- Chain E: S.357, N.361
- Ligands: NAG-NAG.12
Ligand excluded by PLIPNAG.40: 2 residues within 4Å:- Chain E: N.308, T.363
Ligand excluded by PLIPNAG.41: 6 residues within 4Å:- Chain E: N.265, T.267, H.299, N.301, T.383, R.412
Ligand excluded by PLIPNAG.42: 4 residues within 4Å:- Chain E: Q.263, N.265, N.301, S.303
Ligand excluded by PLIPNAG.43: 4 residues within 4Å:- Chain E: N.232, S.261, N.416
- Ligands: NAG-NAG-BMA-MAN-MAN-MAN.13
Ligand excluded by PLIPNAG.44: 4 residues within 4Å:- Chain E: N.271, I.292, G.409, V.410
Ligand excluded by PLIPNAG.45: 4 residues within 4Å:- Chain E: Q.100, S.120, F.121, N.122
Ligand excluded by PLIPNAG.46: 4 residues within 4Å:- Chain A: R.278
- Chain E: R.162, N.167, T.168
Ligand excluded by PLIPNAG.47: 1 residues within 4Å:- Chain E: N.103
Ligand excluded by PLIPNAG.48: 1 residues within 4Å:- Chain E: N.324
Ligand excluded by PLIPNAG.49: 4 residues within 4Å:- Chain E: E.238, E.239, N.259, E.260
Ligand excluded by PLIPNAG.50: 3 residues within 4Å:- Chain F: N.107, E.110
- Chain G: T.56
Ligand excluded by PLIPNAG.51: 4 residues within 4Å:- Chain I: N.204, E.245, N.246
- Ligands: NAG-NAG.19
Ligand excluded by PLIPNAG.52: 3 residues within 4Å:- Chain I: S.357, N.361
- Ligands: NAG-NAG.20
Ligand excluded by PLIPNAG.53: 2 residues within 4Å:- Chain I: N.308, T.363
Ligand excluded by PLIPNAG.54: 6 residues within 4Å:- Chain I: N.265, T.267, H.299, N.301, T.383, R.412
Ligand excluded by PLIPNAG.55: 4 residues within 4Å:- Chain I: Q.263, N.265, N.301, S.303
Ligand excluded by PLIPNAG.56: 4 residues within 4Å:- Chain I: N.232, S.261, N.416
- Ligands: NAG-NAG-BMA-MAN-MAN-MAN.21
Ligand excluded by PLIPNAG.57: 4 residues within 4Å:- Chain I: N.271, I.292, G.409, V.410
Ligand excluded by PLIPNAG.58: 4 residues within 4Å:- Chain I: Q.100, S.120, F.121, N.122
Ligand excluded by PLIPNAG.59: 4 residues within 4Å:- Chain E: R.278
- Chain I: R.162, N.167, T.168
Ligand excluded by PLIPNAG.60: 1 residues within 4Å:- Chain I: N.103
Ligand excluded by PLIPNAG.61: 1 residues within 4Å:- Chain I: N.324
Ligand excluded by PLIPNAG.62: 4 residues within 4Å:- Chain I: E.238, E.239, N.259, E.260
Ligand excluded by PLIPNAG.63: 3 residues within 4Å:- Chain J: N.107, E.110
- Chain K: T.56
Ligand excluded by PLIP- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Martin, J.T. et al., Targeting HIV Env immunogens to B cell follicles in nonhuman primates through immune complex or protein nanoparticle formulations. NPJ Vaccines (2020)
- Release Date
- 2020-08-12
- Peptides
- Envelope glycoprotein gp160: AEI
BG505 SOSIPv5.2 gp41: BFJ
RM19R Kappa Light Chain: CGK
RM19R Heavy Chain: DHL - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AE
CI
DB
BF
EJ
FC
LG
JK
KD
HH
GL
I
- Coordinates
- PDB Format
- Method
- ELECTRON MICROSCOPY
- Oligo State
- hetero-3-3-3-3-mer
- Ligands
- 18 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 3 x NAG- NAG- BMA- MAN- MAN- MAN: alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 3 x NAG- NAG- FUC: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-[alpha-L-fucopyranose-(1-6)]2-acetamido-2-deoxy-beta-D-glucopyranose
- 39 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Martin, J.T. et al., Targeting HIV Env immunogens to B cell follicles in nonhuman primates through immune complex or protein nanoparticle formulations. NPJ Vaccines (2020)
- Release Date
- 2020-08-12
- Peptides
- Envelope glycoprotein gp160: AEI
BG505 SOSIPv5.2 gp41: BFJ
RM19R Kappa Light Chain: CGK
RM19R Heavy Chain: DHL - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AE
CI
DB
BF
EJ
FC
LG
JK
KD
HH
GL
I